| Bioactivity | [1',2',3',4',5'-13C5]Inosine is the 13C5 labeled Inosine (HY-N0092)[1]. | ||||||||||||
| Invitro | 氢、碳和其他元素的稳定重同位素已被纳入药物分子中，主要作为药物开发过程中定量的示踪剂。氘化引起了人们的关注，因为它可能影响药物的药代动力学和代谢谱[1]。 | ||||||||||||
| Name | [1',2',3',4',5'-13C5]Inosine | ||||||||||||
| Formula | C513C5H6N4O5 | ||||||||||||
| Molar Mass | 273.14 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-239. |